Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Abstract Background and Aims Ustekinumab is approved for the treatment of Crohn's
disease [CD]. Systematically registered prospective real-world data are scarce. We therefore …

Background & Aims Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23,
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …

In assessing the best evidence for optimizing management of inflammatory bowel disease
(IBD), the focus is typically on anti-inflammatory agents and therapies that modulate the …

Background Ustekinumab is a monoclonal antibody targeting interleukins‐12 and‐23, with
efficacy in Crohn's disease (CD) demonstrated in clinical trials. Aim To assess the real‐world …

Background Ustekinumab is a fully human monoclonal antibody against IL-12/23.
Ustekinumab induced clinical response and maintained higher rate of response than …

Introduction Ustekinumab, an interleukin-12 and interleukin-23 antagonist, is licensed for the
treatment of Crohn's disease (CD) and ulcerative colitis (UC) after the phase III trial …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

Background Increased knowledge of pathways involved in the pathogenesis of IBD has led
to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis …